HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Goldsmith, P. Articles by Ray, J. Search for Related Content PubMed Articles by Goldsmith, P. Articles by Ray, J.

How Good at Neurology are you? – Answers

^* Departments of Neurology and
Neurophysiology, Addenbrooke’s Hospital, Cambridge, UK. Email; pg255{at}hermes.cam.ac.uk; drslennox{at}aol.com; j.l.ray{at}medschl.cam.ac.uk

EXTRACT

1.

(d) (HIT)

HIT or heparin induced thrombocytopenia, is divided into type I and II. Type I consists of a mild non-immune thrombocytopenia, often seen within a few days of starting heparin. This is typically transient, requires no intervention and improves despite continued heparin administration. Type II, in contrast, is an immune-mediated, idiosyncractic reaction with potentially severe consequences. Severe thrombocytopenia with haemorrhage, purpura and a platelet count of less than 20, is uncommon, with the complications coming mainly from the associated thrombotic tendency. Both arterial and venous thromboses occur. The thromboses may be seen even with a ‘normal’, albeit falling platelet count. Onset is usually 5–14 days after starting heparin, but can occur earlier if there has been previous heparin exposure. HIT may also occur with low molecular weight heparin, albeit more rarely. Treatment is to stop the heparin and give an alternative anticoagulant.

PNH: paroxysmal nocturnal haemoglobinuria. Chronic ...

[PDF of this article]